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Herbal products, used for centuries in Far Eastern countries, are gaining popularity in
western countries. Surveys indicate that persons with chronic hepatitis C (CHC) often use
herbals, especially silymarin (milk thistle extract), hoping to improve the modest response to
antiviral therapy and reduce side effects. The Hepatitis C Antiviral Long-Term Treatment
Against Cirrhosis (HALT-C) Trial, involving persons with advanced CHC, nonresponders
to prior antiviral therapy but still willing to participate in long-term pegylated interferon
treatment, offered the opportunity to examine the use and potential effects of silymarin.
Among 1145 study participants, 56% had never taken herbals, 21% admitted past use, and
23% were using them at enrollment. Silymarin constituted 72% of 60 herbals used at
enrollment. Among all participants, 67% had never used silymarin, 16% used it in the past,
and 17% used it at baseline. Silymarin use varied widely among the 10 participating study
centers; men were more frequent users than women, as were non-Hispanic whites than
African Americans and Hispanics. Silymarin use correlated strongly with higher education.
No beneficial effect of silymarin was found on serum alanine aminotransferase or hepatitis C
virus (HCV) RNA levels. Univariate analysis showed significantly fewer liver-related symp-
toms and better quality-of-life parameters in users than nonusers, but after reanalysis ad-
justed for covariates of age, race, education, alcohol consumption, exercise, body mass index,
and smoking, only fatigue, nausea, liver pain, anorexia, muscle and joint pain, and general
health remained significantly better in silymarin users. Conclusion: Silymarin users had
similar alanine aminotransferase and HCV levels to those of nonusers but fewer symptoms
and somewhat better quality-of-life indices. Because its use among these HALT-C partici-
pants was self-motivated and uncontrolled, however, only a well-designed prospective study
can determine whether silymarin provides benefit to persons with chronic hepatitis C.
(HEPATOLOGY 2008;47:605-612.)
Abbreviations: CAM, complementary and alternative medications; HALT-C, Hepatitis C Antiviral Long-Term Treatment Against Cirrhosis; HCV, hepatitis C virus;
QOL, quality of life.
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The current recommended treatment for chronichepatitis C virus (HCV) infection is the combi-nation of pegylated interferon and ribavirin.1
This regimen leads to a sustained virologic response rate
of a little over 50%, but the rates differ according to the
infecting genotype, being lower among those with HCV
genotype 1 infection (45%) than among those with geno-
type 2 and 3 infections (80%).2-4 Because of the high rate
of nonresponse in persons infected with genotype 1, the
predominating strain in the United States, and because
antiviral treatment causes frequent, unpleasant and some-
times serious adverse effects, many HCV-infected persons
choose either to supplement antiviral medications with 1
or more herbal products or to reject conventional therapy
altogether and instead rely solely on herbals as an alterna-
tive form of therapy.5,6
Herbals have been used for centuries in China and
other Far East countries and have recently become in-
creasingly popular in western countries.7 Surveys in the
United States demonstrate that use of complementary
and alternative medications (CAM) has increased from
34% of the population in 1990 to 48% in 2004.8,9 The
basis for this increasing interest is the thus far unfounded
belief that, because herbals have been used for hundreds of
years and are “natural” products, they must be effective
and safe.10 Their use is especially prevalent in persons with
chronic diseases, and therefore the fact that those with
chronic liver disease seek primary or adjunctive herbal
treatment is not surprising.5,11 In the United States, sily-
marin (an extract of milk thistle) is the most popular
product taken by those with liver disease.6,12
An opportunity was provided to explore the frequency
of use of herbal supplements and their potential effects in
a large cohort of persons with chronic liver disease by
interviewing all participants in the Hepatitis C Antiviral
Long-Term Treatment against Cirrhosis (HALT-C) Tri-
al13 for this purpose. Eligibility for the trial included a
diagnosis of chronic hepatitis C together with histological
evidence of marked fibrosis or cirrhosis and failure to have
responded to previous therapy for chronic hepatitis C.
These treatment nonresponders, some of whom had been
treated on more than 1 occasion, proved their commit-
ment to conventional therapy by volunteering to partici-
pate in this randomized, controlled trial of long-term
pegylated interferon versus observation for 3.5 years to
determine whether such maintenance therapy could re-
duce progression of the chronic liver disease.
The data collected at baseline indicate that herbal use
was indeed common. Silymarin was found to be the most
frequently used herbal supplement, and its use was asso-
ciated with fewer and milder symptoms of liver disease
and better overall quality of life but no difference in bio-
chemical or virologic markers of chronic hepatitis C.
Patients and Methods
Patient Selection. Patients enrolled at all 10 clinical
centers participated in the study. To enter the trial, par-
ticipants had to have chronic hepatitis C with HCV RNA
detected in serum by the central laboratory at the time of
screening, to have failed to respond previously to at least
12 weeks of interferon-based therapy, and to have under-
gone a liver biopsy that demonstrated bridging fibrosis
(Ishak fibrosis score, 3 or 4) or cirrhosis (Ishak fibrosis
score, 5 or 6).14 Reasons for exclusion were evidence of
hepatic decompensation, other coexistent liver diseases,
serious medical disorders that would preclude treatment
with interferon, previous interferon intolerance, active
use of illicit drugs, active alcohol abuse, a suicide attempt
or hospitalization for depression within the past 5 years,
and a history of a severe or uncontrolled psychiatric con-
dition within the preceding 6 months.
Details of the treatment protocol have been reported
previously.13 Briefly, persons with chronic hepatitis C,
defined by the presence of HCV RNA and histological
evidence of either marked fibrosis or cirrhosis, who had
failed previous treatment that had not consisted of the
now standard pegylated interferon and ribavirin, were
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then treated with this therapeutic combination, referred
to as the “lead-in” phase of the trial. If HCV RNA was no
longer detected at week 20, the study subjects continued
the combination treatment for a full 48 weeks. If HCV
RNA was still present, they were randomized at week 24
to receive either pegylated interferon alfa-2a treatment
alone for 3.5 years or to be monitored for the same period
without treatment. Persons who were previous nonre-
sponders to the combination treatment of pegylated in-
terferon and ribavirin were immediately entered into the
3.5-year maintenance phase without passing through
lead-in. Standard demographic, clinical, medication, lab-
oratory, and radiological data were obtained during base-
line visits at all clinical centers. The data were entered into
a central database maintained by the Data Coordinating
Center (New England Research Institutes, Watertown,
MA).
Medication Interview. Study coordinators at all clin-
ical sites were trained to conduct uniform interviews.
Data collected at the baseline visit included not only clin-
ical information relevant for the treatment trial, but also
information on past and current use of all prescription
and nonprescription drugs, including herbal medications,
dietary supplements, and other botanical products. The
patients were given a card displaying 37 examples of
herbal products listed in alphabetical order and were
asked whether they had ever taken any of them or any
other herbal product at least once a week for 1 month or
longer. The information obtained was entered into the
trial database. At each subsequent study visit, patients
were asked whether they had stopped any of the medica-
tions since the last visit or whether they were taking any
new herbals.
Patients who reported no past or current use of herbals
at the baseline visit were considered to be “never users”;
those who reported past but no current use were consid-
ered “past users only” and those who admitted using herb-
als at baseline were counted as “baseline users,” regardless
of past use. No information was obtained on the length of
time that the baseline users had been taking herbals.
Data Analysis. Data were analyzed with SAS (Statis-
tical Analysis Software, version 9.1, SAS Institute, Cary,
NC) software. Chi-squared and t tests were used to calcu-
late the significance of differences in variables among the
2 categories of herbal product use (never and baseline).
Multivariable associations of herbal use with selected out-
comes were evaluated by analysis of variance.
Results
Among the 1145 study participants who were ques-
tioned, 641 (56%) reported that they had never used
herbals, 235 (21%) stated that they had used them in the
past only, and 269 (23%) admitted to current use at the
time of the baseline evaluation (Fig. 1). Although patients
reported using 60 different herbals, many in combina-
tions, 195 (72%) of the 269 baseline herbal users reported
taking silymarin, by far the most common single herbal
used (Table 1). Focusing on silymarin, 772 (67%) indi-
cated they had never used it, 178 (16%) admitted to tak-
ing it in the past, and 195 (17%) used it at the baseline
visit (Fig. 1). The frequency of use of all herbal products as
well as of silymarin varied widely among the different
participating centers. As shown in Fig. 2, baseline use of
all herbals ranged from 12% and 13% at the Bethesda,
Maryland, and Boston, Massachusetts, sites to 29% and
42% at the Los Angeles, California, and Denver, Colo-
rado, sites. Similarly, silymarin use ranged from 8% and
9% at the Bethesda and Boston locations to 22% and
33% at the Ann Arbor, Michigan, and Denver sites.
Among the 195 patients who were using silymarin at
baseline, their mean age was 50.8 years, not significantly
Fig. 1. Percentages of non-users, past users, and baseline users of all
herbals and silymarin.
Table 1. List of the Top 24 Herbals Used at Baseline
Herbal Product No. of Users Herbal Product No. of Users
1. Silymarin 195 13. Flaxseed 9
2. Green Tea 37 14. Dandelion 7
3. Garlic 29 15. Evening Primrose 7
4. Ginseng 25 16. Licorice 7
5. Ginko 24 17. Olive Leaf Extracts 5
6. Echinacea 22 18. Thymus Extracts 5
7. Grape Seed 19 19. Bilberry 4
8. Melatonin 13 20. Kava Kava 4
9. St. John’s Wort 12 21. Pine Bark 4
10. Saw Palmetto 11 22. Chamomile 3
11. Aloe Vera 10 23. Goldenseal 3
12. Psyllium 10 24. Valerian 3
The numbers do not add up to the 269 baseline users of herbals because many
study participants used more than one product.
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different from those who never used this herbal. Silymarin
was used more frequently by men than women (18.4%
versus 13.5%; P  0.05) and by non-Hispanic whites
than both African Americans and Hispanics (19.4% ver-
sus 8.6% and 10.4%, respectively; P  0.0005) (Table 2).
The highest formal education received was significantly
greater among those who were using silymarin at baseline
than among those who had never used silymarin (P 
0.0001) as well as among the users of the other herbal
products combined when compared with the never users
(0.0024); higher education was also associated strongly
with white race (P  0.0001).
Statistical comparisons presented are between persons
using silymarin at the baseline (enrollment) visit and
those who had never used herbals. The levels of HCV
RNA were not significantly different between silymarin
users and non-users; the mean HCV RNA levels were 6.5
log10 IU/mL in silymarin users at baseline compared with
6.4 log10 IU/mL in those who had never used silymarin
(Table 3). Similarly, no significant difference between
baseline silymarin users and non-users was noted for
mean aspartate aminotransferase (91.6 U/L versus 87.4
U/L) or total serum bilirubin levels (0.8 mg/dL for both).
The mean serum alanine aminotransferase level was sig-
nificantly higher in silymarin users than nonusers (124.5
U/L versus 109.5 U/L; P  0.04), whereas the mean
serum alkaline phosphatase level was significantly (P 
0.0004) lower in users than in non-users (88.5 U/L versus
99.7 U/L); both, however, were in the normal range.
Measures of hepatic synthetic function (serum albumin
and prothrombin time) did not differ between the 2
groups. Baseline silymarin users had lower white blood
cell counts (5.6  103/mm3 versus 6.0  103/mm3; P 
0.03) and higher hemoglobin levels (15.4 g/dL versus
15.0 g/dL; P  0.0001) than nonusers; however, the level
of statistical significance in the hemoglobin level was low-
ered after excluding the Denver site from the analysis
(P  0.01), presumably a consequence of the low oxygen
tension present at the high altitude of the Denver site.
Univariate analysis of symptoms at baseline between
silymarin users and non-users revealed a significantly
lower frequency among silymarin users of fatigue (P 
0.004), nausea (P  0.0001), pain over the liver (P 
0.002), anorexia (P  0.0001), headaches (P  0.05),
muscle and joint pains (P  0.0001), pruritus (P  0.03),
depression (P  0.02), and general wellness (P  0.05)
(Table 4). Also, the Beck BDI Depression Score was sig-
nificantly lower in those using silymarin compared with
those who had never used it (P  0.003). However, when
the analysis was adjusted for the covariates of age, race,
education, total alcohol consumed, exercise, body mass
index, and smoking, the only symptoms that remained
significantly less frequent in users of silymarin were fa-
tigue (P  0.01), nausea (P  0.02), liver pain (P 
Fig. 2. Comparison among 10 clinical centers of use of all herbals
and of silymarin at baseline







Male 827 152 18.4
Female 318 43 13.5
0.0502
Non-Hispanic 844 164 19.4
White
African American 175 15 8.6
Hispanic 96 10 10.4
0.0005
Excluded from the racial categories are 30 persons whose race was listed as
“other”; 6 (20%) of them were using silymarin at baseline.




Never Used Baseline Users
P
n  772 n  195
Mean SD Mean SD
Log10 HCV RNA 6.4 0.5 6.5 0.5 0.08
ALT U/L 109.5 71.1 124.5 96.2 0.04
AST U/L 87.4 58.9 91.6 66.7 0.42
Alk. Phos U/L 99.7 43.1 88.5 38.3 0.0004
Tot. Bil mg/dL 0.8 0.4 0.8 0.4 098
Albumin g/dL 3.9 0.4 3.9 0.4 0.85
INR 1.0 0.1 1.0 0.1 0.57
WBC mm3 6.0 2.0 5.6 1.8 0.03
Hemoglobin g/dL 15.0 1.4 15.4 1.3 0.0001
Abbreviations: Alk.Phos, alkaline phosphatase; SD, standard deviation; Tot.Bil,
total bilirubin; INR, international normalized ratio; WBC, white blood count.
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0.02), anorexia (P  0.01), and muscle and joint pain
(P  0.003) (Table 5).
Similarly, quality-of-life (QOL) domains were mea-
sured and compared between silymarin users and non-
users. Significantly higher QOL scores among silymarin
users were found for 6 of 8 QOL domains and 2 of 3
summary scales: physical functioning (P  0.002), body
pain (P  0.005), general health (P  0.002), vitality
(P  0.03), social functioning (P  0.0004), mental
health (P  0.04), physical summary scale (P  0.003),
and the sexual summary scale (P  0.05) (Table 6). All of
these items became nonsignificant, however, except gen-
eral health (P  0.04) when adjusted for the same covari-
ates of age, race, education, total alcohol consumed,
exercise, body mass index, and smoking.
Discussion
The data in this survey of a population of study sub-
jects who volunteered to participate in a trial of long-term
interferon-based therapy for histologically advanced hep-
atitis C reveal that levels neither of HCV RNA nor of
serum alanine aminotransferase—virological and bio-
chemical markers of virus activity and hepatic inflamma-
tion—were improved in those taking herbals, particularly
silymarin, when compared with those who had never used
herbal products. The absence of an identified positive
relationship between silymarin and the virological and
biochemical parameters of chronic HCV infection is con-
sistent with the prevailing belief about these products, but
is not surprising in view of the uncertainty of the product
purity, the dose used, and the duration of use among
those questioned at baseline, coupled with the fact that
this particular cohort, nonresponders to accepted stan-
dard antiviral therapy, are a group especially difficult to
cure. Nevertheless, those who were using silymarin did
have findings of lower frequencies of a limited number of
non–liver-specific symptoms.
Interest in the use of CAM and especially in the use of
herbal products has grown considerably in the United
States in recent years. In a national survey conducted in
1999, an estimated 9.6% of the U.S. population stated
that they had used herbals.15 A similar analysis of data in
the 2002 National Health Interview Survey revealed that
18.6% of 31,044 adult respondents (double the 1999
figure) had used herbs or supplements in the previous 12
months.16 Based on this figure, 38.2 million adults in the
United States were estimated to have used herbals for the
treatment of various health-related conditions.16 Most re-
ported that herbals were important to their health and
well-being, and many were reluctant to inform their phy-
sicians of this use.16
Herbals are often used simply in an effort to improve
well-being and QOL, but they are also commonly em-
Table 6. Univariate Analysis Comparing Baseline Users of
Silymarin to Those Who Had Never Used Silymarin
Quality of Life
Variable
Never Used Baseline Users
P
n  772 n  195
Mean SD Mean SD
Phys. Func 75.0 26.7 81.1 23.4 0.002
Body pain 68.6 26.1 74.3 23.5 0.005
Gen. Health 58.2 22.4 63.7 21.6 0.002
Vitality 53.1 24.6 57.4 22.8 0.03
Soc. Func. 78.9 24.6 85.0 20.3 0.0004
Mental Health 75.9 16.8 78.3 14.3 0.04
Phys Summ Sc 44.0 11.8 46.8 10.9 0.003
Sex Summ Sc 71.0 30.9 75.9 29.1 0.05
Higher scores denote higher quality of life. Abbreviations: SD, standard devi-
ation; Phys.Func, physical functioning; Gen.Health, general; health; Soc.Func,
social functioning; Phys.Summ.Sc, physical summary score; Sex.Summ.Sc, sexual
summary score.
Table 4. Univariate Analysis Comparing Baseline Users of
Silymarin to Those Who Had Never Used Silymarin
Symptoms
Variable
Never Used Baseline Users
P
n  772 n  195
Mean SD Mean SD
Fatigue 3.4 2.6 2.9 2.3 0.004
Nausea 1.0 1.7 0.6 1.0 0.0001
Liver pain 1.8 2.4 1.4 1.8 0.002
Anorexia 1.3 2.0 0.8 1.3 0.0001
Headaches 1.9 2.2 1.5 2.1 0.05
Muscle/joint pain 3.3 2.9 2.4 2.3 0.0001
Pruritus 1.8 2.4 1.4 2.1 0.03
Depression 1.5 2.1 1.2 1.7 0.02
Gen. wellness 2.8 2.3 2.5 1.9 0.05
BDI Dep.Sc. 7.6 7.6 6.1 6.2 0.003
Higher scores denote worse symptom. Abbreviations: Dep, depression; Gen,
general; Sc, score; SD, standard deviation.
Table 5. Multivariate Analysis Comparing Baseline Users of
Silymarin to Those Who Had Never Used Silymarin*
Symptoms and Quality of Life
Variable
Never Used Baseline Users
P
n  731 n  182
Adj. Mean SD Adj. Mean SD
Fatigue 3.4 0.1 2.9 0.2 0.01
Nausea 1.0 0.1 0.7 0.1 0.02
Liver Pain 1.8 0.1 1.4 0.2 0.02
Anorexia 1.3 0.1 0.9 0.1 0.01
Muscle/joint pains 3.2 0.1 2.5 0.2 0.003
General Health 58.8 0.8 62.4 1.6 0.04
*Adjusted for covariates of age, race, education, total number of alcoholic
drinks, exercise, BMI, and smoking. Abbreviation: SD, standard deviation.
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ployed to treat medical ailments, particularly for chronic
diseases.16,17-24 Not surprisingly, therefore, herbals are
used commonly by persons with chronic liver diseases,
especially those with chronic viral hepatitis B and
C.11,12,25-27 Indeed, clinic-based surveys suggest that the
frequency of CAM use among persons with chronic liver
disease ranges between 40% and 50%.5,6
Thus, the results of the current survey are in close
agreement with previously reported experiences; 44% of
the study participants had either previous or current ex-
perience with herbals; 23% continued to take a variety of
herbals even at the time of enrollment; and 17% were
using silymarin either on its own or together with other
herbals. Reliance on herbal remedies might have been
unexpected in this selected study population who had
received conventional antiviral therapy previously—some
more than once—and now were prepared to commit
themselves to an additional 31/2 to 4 years of conven-
tional pegylated interferon–based antiviral therapy.
In keeping with past reports,15,28-30 sex and racial/eth-
nic differences in the use of herbals were observed in this
study population. Also noted was a wide disparity in sily-
marin use among patients enrolled at the 10 different
centers, ranging from a low of 8% to a high of 33%;
silymarin use was reported most frequently among pa-
tients in Colorado, Michigan, and Southern California
and least frequently among those in Maryland and Mas-
sachusetts. The reason for these regional differences and
those reported by others5 is unknown; demographic dif-
ferences in herbal use across the centers in sex, race, or
education did not explain the wide regional disparities in
herbal use (data not shown). Conceivably, local and cul-
tural differences among the populations might have ac-
counted for the variations in the use of alternative
medications, as might the influence of the medical staff
across sites whose attitudes toward CAM practices might
have differed.
Study participants reported using 60 or more herbal prep-
arations, but silymarin was by far the most commonly used
herbal. The popularity of silymarin among patients with
liver disease may derive from the belief that it has a protective
effect in liver injury resulting from Amanita phalloides poi-
soning.31,32 Also, despite failure of clinical trials to demon-
strate silymarin efficacy in any type of liver disease,33,34
silymarin has been postulated to have numerous metabolic
effects that might be hepatoprotective.35-46 Comprehensive
analyses of published data on CAM in general5,6,12,47,48 and
silymarin in particular49,50 for the treatment of liver diseases
including viral hepatitis,51-53 however, provide little convinc-
ing support for the efficacy of such therapies in chronic viral
hepatitis, with the exception of a recent study undertaken in
humans54 as well as an in vitro study using hepatoma Huh 7
cells.55 A possible reason for the absence of demonstrable
silymarin efficacy in viral hepatitis and other liver disorders is
that silymarin formulations studied have not been standard-
ized and that doses administered may have been inadequate.
To address these issues, a multicenter group of investigators
is conducting a clinical trial with standardized formulations
and doses of silymarin to assess its efficacy in chronic hepa-
titis C and nonalcoholic steatohepatitis (ClinicalTrials.gov
Identifier NCT000389376).
An association was noted was between symptoms and
measures of QOL among the silymarin users, who, after
adjustment for the covariates of age, race, education, ex-
ercise, body mass index, and smoking, had lower symp-
tom scores for fatigue, nausea, liver pain, anorexia, and
muscle and joint pains and a higher QOL general health
domain, 1 of 8 domains analyzed. Because these observa-
tions do not represent a prospective and randomized anal-
ysis of CAM use in the study subjects, a definitive
conclusion cannot be reached that the differences en-
countered in these symptom scores between silymarin us-
ers and non-users reflect a clinically meaningful impact of
silymarin.
An issue not explored in this survey is whether liver
injury might have occurred as a result of use of the herbals.
Rich literature exists in regard to herbal hepatotoxici-
ty,10,56 and indeed, 1 of the herbal products claimed to
have been used by a small number of study participants,
kava kava, has been clearly implicated as a cause of drug-
induced liver injury.57 The HALT-C trial was, however,
not designed to detect evidence of hepatotoxicity. More-
over, there is great difficulty in establishing a diagnosis of
drug-induced liver injury when the biochemical abnor-
malities of chronic liver disease already exist.
In conclusion, in the HALT-C trial, involving persons
with chronic HCV infection and advanced liver disease
who had failed to respond previously to 1 or more epi-
sodes of antiviral therapy and were now willing to embark
on a new long-term antiviral treatment trial, approxi-
mately one fifth chose also to use herbals concomitantly.
There was no evidence, however, that silymarin showed
antiviral activity against HCV infection. Moreover, the
observation of better scores in a small number of symp-
toms among silymarin users than in non-users is insuffi-
cient to support the value of this alternative therapy.
Currently in progress, therefore, is a properly designed
prospective, randomized, controlled trial in which a fully
characterized, purified, and standardized silymarin for-
mulation is being evaluated.
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